ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $0 as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-02-18
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $0.00.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.00M; Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed $1.84M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $7.56M.
- 2023-01-01: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $18.99M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-18 | |
| 2024-12-31 | $2.00M 10-K · filed 2026-02-18 | $1.84M 10-K · filed 2025-02-19 |
| 2023-12-31 | $7.56M 10-K · filed 2025-02-19 | |
| 2023-01-01 | $18.99M 10-K · filed 2020-02-14 | |
| 2022-12-31 | $8.48M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $112.24M 10-K · filed 2023-02-17 | |
| 2020-12-31 | $453.25M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $18.99M 10-K · filed 2022-02-15 | |
| 2018-12-31 | $23.24M 10-K · filed 2022-02-15 | |
| 2017-12-31 | $37.69M 10-K · filed 2021-02-12 | |
| 2016-12-31 | $79.14M 10-K · filed 2020-02-14 | |
| 2015-12-31 | $217.39M 10-K · filed 2019-02-20 | |
| 2014-12-31 | $79.84M 10-K · filed 2018-02-21 | |
| 2013-12-31 | $19.47M 10-K · filed 2017-02-17 | |
| 2012-12-31 | $2.04M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |